UK Markets open in 1 hr 44 mins

Omeros Corporation (OMER)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
17.85-0.58 (-3.15%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close18.43
Open18.17
Bid17.88 x 800
Ask17.89 x 1000
Day's range17.84 - 18.69
52-week range9.25 - 25.46
Volume339,141
Avg. volume786,503
Market cap1.113B
Beta (5Y monthly)1.17
PE ratio (TTM)N/A
EPS (TTM)-2.41
Earnings date01 Mar 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est27.00
  • Omeros’ Narsoplimab Pivotal Trial Data to Be Shared as an Oral Presentation at the European Hematology Association Congress
    Business Wire

    Omeros’ Narsoplimab Pivotal Trial Data to Be Shared as an Oral Presentation at the European Hematology Association Congress

    Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from Omeros’ pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be shared as an oral presentation at the 2021 European Hematology Association (EHA) Virtual Congress. The presentation, entitled Narsoplimab (OMS721) Treatment Contributes to Improvements in Organ Function in Adult Patients with High-Risk Transplant-Associated Thrombotic Microangiopathy, will be delivered by Miguel-Angel Perales, M.D., Chief of Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center.

  • Omeros (OMER) Reports Q1 Loss, Misses Revenue Estimates
    Zacks

    Omeros (OMER) Reports Q1 Loss, Misses Revenue Estimates

    Omeros (OMER) delivered earnings and revenue surprises of 1.96% and -5.74%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

  • Omeros Corporation Reports First Quarter 2021 Financial Results
    Business Wire

    Omeros Corporation Reports First Quarter 2021 Financial Results

    Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2021, which include: